ORLANDO -- Anti-interleukin (IL)-5 receptor alpha monoclonal antibody benralizumab (Fasenra) reduced flares in ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with ...

The novel, oral interleukin-23 inhibitor icotrokinra bested placebo in multiple skin outcomes among adolescent patients with ...

Researchers at the University of Illinois Urbana-Champaign report that extracellular vesicles released into the bloodstream ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works ...

Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that a late-breaking abstract ...

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...